Ocular Therapeutix detailed its outlook during the UBS Global Biopharma Conference in London.
What Ocular Therapeutix’s latest earnings reveal Ocular Therapeutix (OCUL) paired a high profile clinical milestone for AXPAXLI in wet AMD with fresh quarterly numbers. This gives a clearer picture of how the story looks on both science and cash flow. On the financial side, the firm reported Q3 2026 revenue of US$12.87 million, compared with US$14.54 million a year earlier, and a net loss of US$94.78 million, wider than the prior US$69.42 million loss. Over the first nine months of 2026,...
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) will be reporting results this Monday morning. Here’s what to look for.
Ocular Therapeutix Inc (OCUL) is poised to file its AXPAXLI NDA in wet AMD in Q4 2026 on the strength of SOL-1 superiority data, backed by a $530.6 million cash position funding operations into 2028.
We’re taking a close look after earnings.
Here are my two planned trades for today and why small caps aren’t so bad off.
BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in November 2026. Upcoming Investor Conference: UBS Global Biopharma Conference 2026: Date: Tuesday, November 17, 2026Fireside Chat: 12:00 – 12:30 PM GMTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLoca
Ocular Therapeutix's AXPAXLI's strong Phase 3 SOL-1 results support a clear regulatory path, with NDA filing expected in Q4. See why I rate OCUL stock a Buy.
Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.
Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.
Detailed price information for Excelerate Energy Inc Cl A (EE-N) from The Globe and Mail including charting and trades.
Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.
BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to fifteen newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq List
2026-10-06. The following slide deck was published by Ocular Therapeutix, Inc.
Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.
OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their eye-disease drugs.
BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026. Upcoming Investor Conference: Chardan 10th Annual Healthcare Conference:Date: Tuesday, October 20, 2026Fireside Chat: 9:45 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Ne
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
We’re buying more shares after a harsh day for the position.
A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.
The small-cap firm is likely to see defense by professional managers.
This is the newest page. Registered accounts read further back.